REG - AstraZeneca PLC - Notice of AGM

AstraZenecaAnnouncement

Tue 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260310:nRSJ0659Wa&default-theme=true

RNS Number : 0659W  AstraZeneca PLC  10 March 2026

 

10 March 2026

 

 

Notice of Annual General Meeting

 

 

AstraZeneca PLC (the Company) announced today the publication of its Notice of
Annual General Meeting 2026 and Shareholders' Circular (the Notice).

 

The Company's Annual General Meeting (AGM) will be digitally-enabled and will
be held on Thursday 9 April 2026 at 14:30 (BST). Full details and joining
instructions are set out in the Notice.

 

The Notice, proxy form and 2020 Performance Share Plan rules have been
submitted to the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . The Notice is also
available on the Company's website at www.astrazeneca.com/noticeofmeeting2026.
(http://www.astrazeneca.com/noticeofmeeting2026)

 

The Notice is being despatched to shareholders today.

 

The business to be conducted at the AGM is summarised below:

1.  To receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December 2025

2.   To confirm the 2025 interim dividends

3.   To appoint KPMG LLP as Auditor

4.   To authorise the Directors to agree the remuneration of the Auditor

5.   To re-elect Directors

6.  To approve the annual statement of the Chair of the Remuneration
Committee and the Annual    Report on Remuneration for the year ended 31
December 2025

7.  To renew the authorisation to grant awards under the French Appendix 3 of
the AstraZeneca   Performance Share Plan 2020

8.   To authorise limited political donations

9.   To authorise the Directors to allot shares

10. To authorise the Directors to disapply pre-emption rights

11. To authorise the Directors to further disapply pre-emption rights for
acquisitions and specified capital investments

12. To authorise the Company to purchase its own shares

13. To reduce the notice period for general meetings

 

Holders of ordinary shares listed on the New York Stock Exchange entered in
the register of members of the Company by 18:30 (BST) on 7 April 2026 (or
their duly appointed proxies), or if this meeting is adjourned, in the
register of members by 18:30 (UK time) two UK business days prior to any
adjourned meeting, are entitled to participate and vote at the AGM in respect
of the number of ordinary shares registered in their name at that time.

Holders of AstraZeneca PLC UK Depositary Interests (UK DIs) in the AstraZeneca
PLC Corporate Sponsored Nominee facility (CSN Holders) entered in the
Company's register of CSN Holders (the CSN Register) as at 18:00 (BST) on 1
April 2026 or, if the meeting is adjourned, at 18:00 (UK time) on the day
which is four UK business days before the day of the adjourned meeting, shall
be entitled to provide voting instructions to Computershare Investor Services
Plc (in accordance with the notes set out in the Notice) in respect of the
number of UK DIs that such holders are beneficially entitled to at that time.

Registered holders of UK DIs other than UK DIs held via the AstraZeneca PLC
Corporate Sponsored Nominee facility (UK DI Holders) entered in the Company's
register of UK DI Holders (the DI Register) as at 18:00 (BST) on 1 April 2026
or, if the meeting is adjourned, at 18:00 (UK time) on the day which is four
UK business days before the day of the adjourned meeting, shall be entitled to
provide voting instructions to Computershare Investor Services Plc (in
accordance with the notes set out in the Notice) in respect of the number of
UK DIs registered in their name at that time.

The Record Date applied to the Euroclear Sweden system for this AGM is close
of business on 27 March 2026. Holders of ordinary shares listed on Nasdaq
Stockholm at the Record Date are entitled to vote and participate in the AGM
in respect of the number of shares held at the Record Date.

Changes to the entries in the: (i) register of members of the Company; (ii)
CSN Register; (iii) DI Register; or (iv) records held in the Euroclear Sweden
system, after the respective record dates and times set out above, shall be
disregarded in determining the rights of any person to participate or vote at
the AGM.

Holders of ordinary shares or UK DIs through a nominee account, broker or bank
should refer to the information provided by their account provider (as well as
the notes set out in the Notice) for the relevant voting deadlines that apply
to them.

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGPUCWWUPQGUU



            Copyright 2019 Regulatory News Service, all rights reserved